Answers are grounded in this paper and cite their sources.
BACKGROUND: Quality indicators (QIs) are central to safe delivery of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), yet program-level benchmarking across tumor types is scarce. OBJECTIVES: To describe the structure, process, and outcome QIs of a single-center CRS-HIPEC program (2014-2024) and to assess temporal trends in cytoreduction completeness, early mortality, length of stay (LOS), renal safety, and multidisciplinary team (MDT) integration against contemporary international benchmarks. MATERIAL AND METHODS: A retrospective cohort study of consecutive CRS-HIPEC procedures (2014-2024) was conducted at a Polish tertiary center. Prespecified QIs included complete or near-complete cytoreduction (CC-0/1), 30- and 90-day mortality, LOS, LOS > 10 days, unplanned reoperation, 30-day readmission, MDT uptake, and acute kidney injury (AKI; defined using Kidney Disease: Improving Global Outcomes (KDIGO) serum creatinine criteria). Time trends were displayed with Shewhart charts and funnel plots; Wilson's 95% confidence intervals (95% CIs) were used for proportions. RESULTS: Among 319 procedures (colorectal cancer (CRC) 111; ovarian cancer 87; mesothelioma/other 57; low-grade appendiceal mucinous neoplasm/pseudomyxoma peritonei (LAMN/PMP) 52; gastric cancer 12), the CC-0/1 rate was 93.4% overall (CRC 96.4%; LAMN/PMP 100%; ovarian cancer 90.8%; gastric cancer 91.7%; mesothelioma/other 86.0%). Thirtyand 90-day mortality were 0.6% and 1.6%, respectively; tumor-specific 30-day mortality ranged from 0% to 1.9%. Median LOS fell from 8.6 to 7.4 days (2014-2018 vs 2019-2024), and LOS > 10 days declined from 25.0% to 13.2%. Peritoneal cancer index (PCI) correlated weakly with LOS (Spearman's ρ = 0.13, p = 0.019), while AKI occurred in 70/308 (22.7%, 95% CI: 18.4-27.7), predominantly stage 1; AKI did not differ by cisplatin exposure (26.0% vs 21.2%, p = 0.389). The proportion of procedures with documented MDT discussion increased to approx. 20-33% after 2018. CONCLUSIONS: Over 11 years, a single-center CRS-HIPEC program achieved high-quality cytoreduction with low early mortality and a reduction in LOS, meeting or exceeding contemporary QI standards. Incorporating AKI and MDT uptake into routine audit supports comprehensive, program-level benchmarking.
No takes yet. Share an insight, caveat, or question.
Kazanowski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: